NPJ Aging Mech Dis. 2021 Jan 04;7(1):2. doi: 10.1038/s41514-020-00052-5.

Differential transcript usage unravels gene expression alterations in Alzheimer's disease human brains.

NPJ aging and mechanisms of disease

Diego Marques-Coelho, Lukas da Cruz Carvalho Iohan, Ana Raquel Melo de Farias, Amandine Flaig, Jean-Charles Lambert, Marcos Romualdo Costa

PMID: 33398016 PMCID: PMC7782705 DOI: 10.1038/s41514-020-00052-5

Abstract

Alzheimer's disease (AD) is the leading cause of dementia in aging individuals. Yet, the pathophysiological processes involved in AD onset and progression are still poorly understood. Among numerous strategies, a comprehensive overview of gene expression alterations in the diseased brain could contribute for a better understanding of the AD pathology. In this work, we probed the differential expression of genes in different brain regions of healthy and AD adult subjects using data from three large transcriptomic studies: Mayo Clinic, Mount Sinai Brain Bank (MSBB), and ROSMAP. Using a combination of differential expression of gene and isoform switch analyses, we provide a detailed landscape of gene expression alterations in the temporal and frontal lobes, harboring brain areas affected at early and late stages of the AD pathology, respectively. Next, we took advantage of an indirect approach to assign the complex gene expression changes revealed in bulk RNAseq to individual cell types/subtypes of the adult brain. This strategy allowed us to identify previously overlooked gene expression changes in the brain of AD patients. Among these alterations, we show isoform switches in the AD causal gene amyloid-beta precursor protein (APP) and the risk gene bridging integrator 1 (BIN1), which could have important functional consequences in neuronal cells. Altogether, our work proposes a novel integrative strategy to analyze RNAseq data in AD and other neurodegenerative diseases based on both gene/transcript expression and regional/cell-type specificities.

References

1. Masters, C. L. et al. Alzheimer’s disease. Nat. Rev. Dis. Primers 1, 15056 (2015). - PubMed
2. Allen, M. et al. Human whole genome genotype and transcriptome data for Alzheimer’s and other neurodegenerative diseases. Sci. Data 3, 160089 (2016). - PubMed
3. De Jager, P. L. et al. Data descriptor: a multi-omic atlas of the human frontal cortex for aging and Alzheimer’s disease research. Sci. Data 5, 180142–180142 (2018). - PubMed
4. Wang, M. et al. The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer’s disease. Sci. Data 5, 1–16 (2018). - PubMed
5. Raj, T. et al. Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer’s disease susceptibility. Nat. Genet. 50, 1584–1592 (2018). - PubMed
6. Grubman, A. et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer’s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci. 22, 2087–2097 (2019). - PubMed
7. Mathys, H. et al. Single-cell transcriptomic analysis of Alzheimer’s disease. Nature 570, 332–337 (2019). - PubMed
8. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 82, 239–259 (1991). - PubMed
9. Xu, J. et al. Regional protein expression in human Alzheimer’s brain correlates with disease severity. Commun. Biol. 2, 1–15 (2019). - PubMed
10. Yi, L., Pimentel, H., Bray, N. L. & Pachter, L. Gene-level differential analysis at transcript-level resolution. Genome Biol. 19, 53 (2018). - PubMed
11. Anders, S., Reyes, A. & Huber, W. Detecting differential usage of exons from RNA-seq data. Genome Res. 22, 2008–2017 (2012). - PubMed
12. Vitting-Seerup, K. & Sandelin, A. IsoformSwitchAnalyzeR: analysis of changes in genome-wide patterns of alternative splicing and its functional consequences. Bioinformatics 35, 4469–4471 (2019). - PubMed
13. Canchi, S. et al. Integrating gene and protein expression reveals perturbed functional networks in Alzheimer’s disease. Cell Rep. 28, 1103–1116.e4 (2019). - PubMed
14. Van den Berge, K., Soneson, C., Robinson, M. D. & Clement, L. stageR: a general stage-wise method for controlling the gene-level false discovery rate in differential expression and differential transcript usage. Genome Biol. 18, 151 (2017). - PubMed
15. Abuznait, A. H. & Kaddoumi, A. Role of ABC transporters in the pathogenesis of Alzheimers disease. ACS Chem. Neurosci. 3, 820–831 (2012). - PubMed
16. Benoit, M. E. et al. C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models are essential for the C1q-mediated protection against amyloid- β neurotoxicity. J. Biol. Chem. 288, 654–665 (2013). - PubMed
17. Zullo, J. M. et al. Regulation of lifespan by neural excitation and REST. Nature 574, 359–364 (2019). - PubMed
18. Prévot, T. & Sibille, E. Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders. Mol. Psychiatry 1–17 (2020) https://www.nature.com/articles/s41380-020-0727-3 . - PubMed
19. Beckmann, N. D. et al. Multiscale causal networks identify VGF as a key regulator of Alzheimer’s disease. Nat. Commun. 11, 18 (2020). - PubMed
20. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005). - PubMed
21. Vitting-Seerup, K. & Sandelin, A. The landscape of isoform switches in human cancers. Mol. Cancer Res. 15, 1206–1220 (2017). - PubMed
22. Kamenetz, F. et al. APP processing and synaptic function. Neuron 37, 925–937 (2003). - PubMed
23. Alberi, S. et al. The endosomal protein NEEP21 regulates AMPA receptor-mediated synaptic transmission and plasticity in the hippocampus. Mol. Cell. Neurosci. 29, 313–319 (2005). - PubMed
24. Norstrom, E. M., Zhang, C., Tanzi, R. & Sisodia, S. S. Identification of NEEP21 as a β-amyloid precursor protein-interacting protein in vivo that modulates amyloidogenic processing in vitro. J. Neurosci. 30, 15677–15685 (2010). - PubMed
25. Yu, N. N., Tan, M. S., Yu, J. T., Xie, A. M. & Tan, L. The role of reelin signaling in Alzheimer’s disease. Mol. Neurobiol. 53, 5692–5700 (2016). - PubMed
26. Limon, A., Reyes-Ruiz, J. M. & Miledi, R. Loss of functional GABA A receptors in the Alzheimer diseased brain. Proc. Natl Acad. Sci. USA 109, 10071–10076 (2012). - PubMed
27. Wan, Y. W. et al. Meta-analysis of the Alzheimer’s disease human brain transcriptome and functional dissection in mouse models. Cell Rep. 32, 107908 (2020). - PubMed
28. Raj, B. & Blencowe, B. J. Alternative splicing in the mammalian nervous system: recent insights into mechanisms and functional roles. Neuron 87, 14–27 (2015). - PubMed
29. Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 45, 1452–1458 (2013). - PubMed
30. Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat. Genet. 51, 414–430 (2019). - PubMed
31. Dourlen, P., Kilinc, D., Malmanche, N., Chapuis, J. & Lambert, J. C. The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? Acta Neuropathologica 138, 221–236 (2019). - PubMed
32. Zhou, Y. et al. Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein Tau in Alzheimer’s disease. PLoS ONE 9, e103187 (2014). - PubMed
33. Kitaguchi, N., Takahashi, Y., Tokushima, Y., Shiojiri, S. & Ito, H. Novel precursor of Alzheimer’s disease amyloid protein shows protease inhibitory activity. Nature 331, 530–532 (1988). - PubMed
34. Johnson, S. A., Rogers, J. & Finch, C. E. APP-695 transcript prevalence is selectively reduced during Alzheimer’s disease in cortex and hippocampus but not in cerebellum. Neurobiol. Aging 10, 755–760 (1989). - PubMed
35. Tanzi, R. E. et al. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s disease. Nature 331, 528–530 (1988). - PubMed
36. Lee, T. I. & Young, R. A. Transcriptional regulation and its misregulation in disease. Cell 152, 1237–1251 (2013). - PubMed
37. Haroutunian, V., Katsel, P. & Schmeidler, J. Transcriptional vulnerability of brain regions in Alzheimer’s disease and dementia. Neurobiol. Aging 30, 561–573 (2009). - PubMed
38. Costa-Silva, J., Domingues, D. & Lopes, F. M. RNA-Seq differential expression analysis: an extended review and a software tool. PLoS ONE 12, e0190152 (2017). - PubMed
39. Canter, R. G., Penney, J. & Tsai, L. H. The road to restoring neural circuits for the treatment of Alzheimer’s disease. Nature 539, 187–196 (2016). - PubMed
40. Milind, N. et al. Transcriptomic stratification of late-onset Alzheimer’s cases reveals novel genetic modifiers of disease pathology. PLoS Genet. 16, e1008775 (2020). - PubMed
41. Odero, G. L. et al. Evidence for the involvement of calbindin D28k in the presenilin 1 model of Alzheimer’s disease. Neuroscience 169, 532–543 (2010). - PubMed
42. Verret, L. et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in alzheimer model. Cell 149, 708–721 (2012). - PubMed
43. Mehr, A. et al. Lack of APP and APLP2 in GABAergic forebrain neurons impairs synaptic plasticity and cognition. Cereb. Cortex 30, 4044–4063 (2020). - PubMed
44. Dörrbaum, A. R., Alvarez-Castelao, B., Nassim-Assir, B., Langer, J. D. & Schuman, E. M. Proteome dynamics during homeostatic scaling in cultured neurons. eLife 9, e52939 (2020). - PubMed
45. Alam, S., Suzuki, H. & Tsukahara, T. Alternative splicing regulation of APP exon 7 by RBFox proteins. Neurochem. Int. 78, 7–17 (2014). - PubMed
46. Lee, M. H. et al. Somatic APP gene recombination in Alzheimer’s disease and normal neurons. Nature 563, 639–645 (2018). - PubMed
47. Glennon, E. B. C. et al. BIN1 is decreased in sporadic but not familial Alzheimer’s disease or in aging. PLoS ONE 8, e78806 (2013). - PubMed
48. Sartori, M. et al. BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts with Tau through Thr348 phosphorylation. Acta Neuropathologica 138, 631–652 (2019). - PubMed
49. Strotzer, M. One century of brain mapping using Brodmann areas. Clin. Neuroradiol. 19, 179–186 (2009). - PubMed
50. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525–527 (2016). - PubMed
51. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014). - PubMed
52. Love, M. I., Soneson, C. & Patro, R. Swimming downstream: statistical analysis of differential transcript usage following Salmon quantification. F1000Research 7, 952–952 (2018). - PubMed
53. Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences [version 2; referees: 2 approved]. F1000Research 4, 1521 (2016). - PubMed
54. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018). - PubMed
55. Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J. & Peterson, H. gprofiler2—an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. F1000Research 9, 709 (2020). - PubMed
56. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012). - PubMed

Publication Types

• Journal Article